Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) reported Q3 EPS of ($1.36), $0.16 worse than the analyst estimate of ($1.20). Revenue for the quarter came in at $75.23 million versus the consensus estimate of $52.66 million.

For earnings history and earnings-related data on Arrowhead Pharmaceuticals Inc. (ARWR) click here.